Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
# C; @; S) m h" O& lNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 2 K& j- _! c7 z5 G. F/ _ Y Y! [
+ Author Affiliations
: N& v* h& \& O4 ?1 p5 H7 p
' C# d2 e5 I, t- k1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 4 P5 x. ^+ _! {
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan % U+ ?( ?* ~2 C( p
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
# G$ _ p9 I" L9 m# U. ` w% n4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
. |8 T( S" N0 [7 }! B5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 5 q- z* ?! H$ R3 H% L9 U/ B" G
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
6 `( U0 `( P) [( h$ E7Kinki University School of Medicine, Osaka 589-8511, Japan
& u1 ?* s- G. M$ Q8Izumi Municipal Hospital, Osaka 594-0071, Japan 7 u6 ~0 H; H. E% v) J% t+ X
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
1 A8 L& Z0 P( B) uCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ; H! F, ?' o* g' s
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 6 J' ?9 q! e! t% E6 {4 \
4 M) }! I4 m* T% c1 c S |